YONGCHENG SONG to Humans
This is a "connection" page, showing publications YONGCHENG SONG has written about Humans.
Connection Strength
0.390
-
Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease. ACS Infect Dis. 2024 02 09; 10(2):715-731.
Score: 0.024
-
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery. Drug Discov Today. 2024 Jan; 29(1):103832.
Score: 0.024
-
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Eur J Med Chem. 2023 Nov 15; 260:115772.
Score: 0.024
-
Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP. Eur J Med Chem. 2022 Jul 05; 237:114407.
Score: 0.021
-
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J Hematol Oncol. 2022 04 08; 15(1):41.
Score: 0.021
-
Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021 04 06; 14(1):56.
Score: 0.020
-
Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. J Med Chem. 2021 03 11; 64(5):2777-2800.
Score: 0.020
-
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020 05 13; 13(1):50.
Score: 0.019
-
Thermodynamic investigation of DNA-binding affinity of wild-type and mutant transcription factor RUNX1. PLoS One. 2019; 14(5):e0216203.
Score: 0.017
-
Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics. 2018; 8(8):2189-2201.
Score: 0.016
-
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Med Chem. 2018; 14(7):715-724.
Score: 0.016
-
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. PLoS One. 2017; 12(2):e0170301.
Score: 0.015
-
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
Score: 0.014
-
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. J Med Chem. 2016 Jan 14; 59(1):253-263.
Score: 0.014
-
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. J Med Chem. 2015 Sep 10; 58(17):6899-6908.
Score: 0.013
-
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget. 2014 Nov 15; 5(21):10665-77.
Score: 0.013
-
A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. J Med Chem. 2013 Nov 27; 56(22):8972-83.
Score: 0.012
-
Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem. 2012 Sep 27; 55(18):8066-74.
Score: 0.011
-
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc. 2011 Oct 26; 133(42):16746-9.
Score: 0.010
-
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. J Med Chem. 2009 Nov 12; 52(21):6539-42.
Score: 0.009
-
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors. J Virol. 2025 Feb 25; 99(2):e0175724.
Score: 0.006
-
Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
Score: 0.006
-
A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proc Natl Acad Sci U S A. 2023 Oct 31; 120(44):e2307793120.
Score: 0.006
-
Norovirus Protease Structure and Antivirals Development. Viruses. 2021 10 14; 13(10).
Score: 0.005
-
Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha. Commun Biol. 2020 04 07; 3(1):165.
Score: 0.005
-
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81.
Score: 0.004
-
Antiviral targets of human noroviruses. Curr Opin Virol. 2016 06; 18:117-25.
Score: 0.004
-
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 03; 7(18):26307-30.
Score: 0.004
-
Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. Nat Commun. 2014 Nov 17; 5:5476.
Score: 0.003
-
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. J Med Chem. 2014 Oct 23; 57(20):8307-18.
Score: 0.003
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.003
-
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One. 2014; 9(5):e98270.
Score: 0.003
-
Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS One. 2013; 8(7):e69646.
Score: 0.003
-
Biochemical control of CARM1 enzymatic activity by phosphorylation. J Biol Chem. 2009 Dec 25; 284(52):36167-36174.
Score: 0.002